A Phase 1 interventional study of Tirabrutinib and Idelalisib in B-cell Malignancies, sponsored by Gilead Sciences. Terminated at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the long-term safety of tirabrutinib as a monotherapy and in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies.
This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and in combination with other anti-cancer therapies. As of Amendment 9, all participants currently on the study who have no clinical evidence of disease progression will transition into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to receive treatment via named patient use (or individual expanded use) will be enrolled into the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any participant is an additional 6 years from the date of this amendment (ie. until November 2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to participants who are currently receiving entospletinib. Participants treated with entospletinib as part of a combination regimen with tirabrutinib will stop receiving entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg tablets until study completion. Participants assigned to the 50 mg tablet will be given the option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Long-term Safety Monitoring group only (Group VI):
Key Exclusion Criteria:
Long-term Safety Monitoring group only (Group VI):
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tirabrutinib 20 mg tablet once daily (QD) for up to 209 weeks and idelalisib 50 mg tablet twice daily (BID) orally for up to 120 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib
Participants will receive tirabrutinib 40 mg tablet QD for up to 251 weeks and idelalisib 50 mg tablet BID orally, for up to 245 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib
Participants will receive tirabrutinib 80 mg tablet QD for up to 212 weeks and idelalisib 50 mg tablet BID orally, for up to 26 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib
Participants will receive tirabrutinib 80 mg tablet QD for up to 227 weeks and idelalisib 100 mg tablet QD orally, for up to 227 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib
Participants will receive tirabrutinib 160 mg tablet QD for up to 151 weeks and idelalisib 100 mg tablet QD orally, for up to 151 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib
Participants will receive tirabrutinib 20 mg tablet BID for up to 207 weeks and idelalisib 50 mg tablet BID orally, for up to 207 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib
Participants will receive tirabrutinib 40 mg tablet QD for up to 250 weeks and entospletinib 200 mg tablet QD orally, for up to 250 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib
Participants will receive tirabrutinib 80 mg tablet QD for up to 234 weeks and entospletinib 200 mg tablet QD orally, for up to 220 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib
Participants will receive tirabrutinib 150 mg tablet QD for up to 103 weeks and entospletinib 200 mg tablet QD orally, for up to 88 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib
Participants will receive tirabrutinib 40 mg tablet QD for up to 119 weeks and entospletinib 400 mg tablet QD orally, for up to 119 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib
Participants will receive tirabrutinib 80 mg tablet QD for up to 232 weeks and entospletinib 400 mg tablet QD orally, for up to 229 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib
Participants will receive tirabrutinib 160 mg tablet QD for up to 44 weeks and entospletinib 400 mg tablet QD orally, for up to 44 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib
Participants will receive tirabrutinib 80 mg tablet QD for up to 199 weeks; Idelalisib 100 mg tablet QD orally for up to 199 weeks, and single dose of obinutuzumab 1000 mg intravenously (IV) for up to 22 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Idelalisib · Drug: Obinutuzumab
Participants will receive tirabrutinib 80 mg tablet QD for up to 196 weeks; entospletinib 400 mg tablet QD orally for up to 196 weeks and single dose of obinutuzumab 1000 mg IV for up to 22 weeks. Both drugs will be administered for 28-day cycles.
Drug: Tirabrutinib · Drug: Entospletinib · Drug: Obinutuzumab
Participants will receive tirabrutinib 80 mg tablet QD orally, for each 28-day cycle up to 194 weeks.
Drug: Tirabrutinib
Participants with CLL who received tirabrutinib in this or a previous tirabrutinib study will continue to receive tirabrutinib at the original dose (between the range of 40 - 400 mg), tablet QD, for each 28-day cycle up to 441 weeks. Participants will be monitored for the long-term safety of tirabrutinib in this group.
Drug: Tirabrutinib
Participants with NHL who received tirabrutinib in this or a previous tirabrutinib study will continue to receive tirabrutinib at the original dose (between the range of 60 - 480 mg), tablet QD, for each 28-day cycle up to 441 weeks. Participants will be monitored for the long-term safety of tirabrutinib in this group.
Drug: Tirabrutinib
Capsules or tablets administered orally
Also known as: ONO/GS-4059
Tablets administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL-101
Tablets administered orally
Also known as: GS-9973
Administered intravenously
Percentage of Participants With Dose Limiting Toxicities (DLTs)
A DLT was defined as a ≥ Grade 3 AE that was assessed as related to study drug that occurred during the 28-day DLT assessment period with protocol-defined allowed exceptions. Any treatment-emergent adverse event (TEAE) that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.
Time frame: Up to 28 days
Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) at Week 12 in Participants With Non-Chronic Lymphocytic Leukemia (CLL) Type NHL
ORR for Waldenstrom Macroglobulinemia(WM):CR+VGPR+PR+MPR. CR: Absence of serum monoclonal IgM protein; normal serum IgM level: complete resolution of extramedullary disease, morphologically normal bone marrow/aspirate and trephine biopsy. Very good partial response (VGPR):Detectable monoclonal IgM; ≥90% reduction in serum IgM; Complete resolution of extramedullary disease; No new signs/symptoms. PR: Monoclonal immunoglobulin M (IgM) protein is detectable ≥50% but \<90% reduction in serum IgM level from baseline; reduction of extramedullary disease; no new signs or symptoms of active disease. Minor response (MPR):Detectable monoclonal IgM; ≥25% but \<50% reduction in serum IgM; No progression of extramedullary disease; No new signs/symptoms. Clopper-Pearson method was used in analysis. Data is reported by disease type: WM; Follicular Lymphoma (FL);Mantle Cell Lymphoma (MCL);Small Lymphocytic Lymphoma (SLL);Marginal Zone Lymphoma (MZL);Diffuse Large B-Cell Lymphoma (DLBCL) as applicable.
Time frame: Week 12
ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). CR and PR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off.
Time frame: Week 24
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.
Time frame: First dose up to last dose date (up to 441 weeks) plus 30 days
ORR: Percentage of Participants With Complete Response (CR) or Partial Response (PR) in the Dose Escalation and Expansion Phase
ORR for WM is CR + VGPR + PR + MPR. CR, PR, VGPR and MPR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off. Data is reported by disease type: CLL ; FL; MCL; MZL; SLL; WM; DLBCL.
Time frame: Up to 281 weeks
Progression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase
PFS was defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression (PD) or death from any cause. PD: ≥ 25% increase in serum IgM level from lowest nadir (requires confirmation) and/or progression in clinical features attributable to the disease. Kaplan-Meier (KM) estimate were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; other NHL; DLBCL.
Time frame: Up to 281 weeks
Duration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase
DOR was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of definite disease progression or death from any cause. CR and PR are defined in outcome measure# 2. PD is defined in outcome measure #6. KM estimates were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL
Time frame: Up to 281 weeks
Time to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase
TTR was defined as the interval from start of treatment to the first documentation of CR or PR. CR and PR are defined in outcome measure# 2. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL.
Time frame: Up to 281 weeks
Percentage of Participants Who Achieved Minimal Residual Negative Disease (< 1 Leukemia Cell/10,000 Leukocytes) During the Dose Escalation Phase and Dose Expansion Phase in Participants With CLL
Achieving Minimal Residual Disease was defined as \< 1 leukemia cell/10,000 leukocytes (10-4) in participants who have also achieved a CR. CR is defined in outcome measure #2.
Time frame: Up to 281 weeks
Pharmacokinetic (PK) Parameter: AUCtau of Tirabrutinib 80 mg
AUCtau was defined as concentration of drug over time. Area under the concentration verses time curve over the dosing interval (AUctau). The data for AUCtau is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: Cmax of Tirabrutinib 80 mg
Cmax was defined as the maximum observed concentration of drug. The data for Cmax is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: AUCtau of Idelalisib When Given in Combination With Tirabrutinib
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: Cmax of Idelalisib When Given in Combination With Tirabrutinib
Cmax was defined as the maximum observed concentration of drug.
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: AUCtau of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: Cmax of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib
Cmax was defined as the maximum observed concentration of drug.
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: AUCtau of Entospletinib When Given in Combination With Tirabrutinib
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
PK Parameter: Cmax of Entospletinib When Given in Combination With Tirabrutinib
Cmax was defined as the maximum observed concentration of drug.
Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Participants were enrolled at study sites in France, the United Kingdom and the United States.
| Milestone | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 8 | 4 | 25 | 9 | 5 | 3 | 6 | 3 | 3 | 78 | 8 | 6 | 7 | 29 | 3 | 3 |
| Rollover participants | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 8 | 4 | 25 | 9 | 4 | 3 | 6 | 3 | 3 | 78 | 8 | 6 | 7 | 29 | 3 | 3 |
| Withdrew: Progressive disease | 2 | 2 | 1 | 11 | 7 | 3 | 2 | 1 | 1 | 2 | 45 | 6 | 2 | 2 | 10 | 1 | 1 |
| Withdrew: Investigator's discretion | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 1 | 2 | 0 | 10 | 2 | 2 | 1 | 5 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 0 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 8 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 4 | 1 | 0 | 0 | 1 | 0 | 1 | 6 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Transition to the mhra's special scheme | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Unacceptable toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Intercurrent illness | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
A DLT was defined as a ≥ Grade 3 AE that was assessed as related to study drug that occurred during the 28-day DLT assessment period with protocol-defined allowed exceptions. Any treatment-emergent adverse event (TEAE) that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.
| percentage of participants | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORR for Waldenstrom Macroglobulinemia(WM):CR+VGPR+PR+MPR. CR: Absence of serum monoclonal IgM protein; normal serum IgM level: complete resolution of extramedullary disease, morphologically normal bone marrow/aspirate and trephine biopsy. Very good partial response (VGPR):Detectable monoclonal IgM; ≥90% reduction in serum IgM; Complete resolution of extramedullary disease; No new signs/symptoms. PR: Monoclonal immunoglobulin M (IgM) protein is detectable ≥50% but \<90% reduction in serum IgM level from baseline; reduction of extramedullary disease; no new signs or symptoms of active disease. Minor response (MPR):Detectable monoclonal IgM; ≥25% but \<50% reduction in serum IgM; No progression of extramedullary disease; No new signs/symptoms. Clopper-Pearson method was used in analysis. Data is reported by disease type: WM; Follicular Lymphoma (FL);Mantle Cell Lymphoma (MCL);Small Lymphocytic Lymphoma (SLL);Marginal Zone Lymphoma (MZL);Diffuse Large B-Cell Lymphoma (DLBCL) as applicable.
| percentage of participants | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Subtype: FL | — | 0 (0 to 84.2) | 0 (0 to 97.5) | 20.0 (0.5 to 71.6) | — | 0 (0 to 84.2) | — | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) | 0 (0 to 97.5) | 18.2 (5.2 to 40.3) | — | 25.0 (0.6 to 80.6) | 40.0 (5.3 to 85.3) | — |
| Disease Subtype: MCL | — | 0 (0 to 97.5) | — | — | — | — | 0 (0 to 97.5) | — | — | — | 60.0 (26.2 to 87.8) | — | 100.0 (2.5 to 100.0) | — | — |
| Disease Subtype: SLL | 50.0 (1.3 to 98.7) | — | — | — | — | — | 0 (0 to 84.2) | — | — | — | — | — | — | — | — |
| Disease Subtype: MZL | — | — | 100.0 (2.5 to 100.0) | 33.3 (0.8 to 90.6) | — | 0 (0 to 97.5) | — | — | — | 0 (0 to 97.5) | 50.0 (6.8 to 93.2) | — | 100.0 (2.5 to 100) | 50.0 (1.3 to 98.7) | — |
| Disease Subtype: WM | — | — | — | 100.0 (39.8 to 100.0) | — | 0 (0 to 97.5) | — | — | — | 0 (0 to 97.5) | 42.9 (9.9 to 81.6) | — | — | — | — |
| Disease Subtype: DLBCL | — | — | 0 (0 to 97.5) | 14.3 (0.4 to 57.9) | 22.2 (2.8 to 60.0) | — | — | 0 (0 to 97.5) | 100.0 (15.8 to 100.0) | — | 17.9 (6.1 to 36.9) | 12.5 (0.3 to 52.7) | — | — | — |
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). CR and PR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off.
| percentage of participants | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24 | 100.0 (2.5 to 100) | 80.0 (28.4 to 99.5) | 100.0 (2.5 to 100) | 66.7 (22.3 to 95.7) | — | 100.0 (2.5 to 100) | — | 66.7 (9.4 to 99.2) | — | — | 28.6 (3.7 to 71) | — | — | — | 79.3 (60.3 to 92) |
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.
| percentage of participants | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 96.2 | 75.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
ORR for WM is CR + VGPR + PR + MPR. CR, PR, VGPR and MPR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off. Data is reported by disease type: CLL ; FL; MCL; MZL; SLL; WM; DLBCL.
| percentage of participants | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+Entospletinib 400 mg QD+ Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Subtype: CLL | 100.0 (2.5 to 100.0) | 100.0 (47.8 to 100.0) | 100.0 (2.5 to 100.0) | 83.3 (35.9 to 99.6) | — | 100.0 (2.5 to 100.0) | — | 100.0 (29.2 to 100.0) | — | — | 100.0 (59 to 100.0) | — | — | — | 86.2 (68.3 to 96.1) |
| Disease Subtype: FL | — | 0 (0 to 84.2) | 0 (0 to 97.5) | 20.0 (0.5 to 71.6) | — | 50.0 (1.3 to 98.7) | — | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) | 100.0 (2.5 to 100.0) | 36.4 (17.2 to 59.3) | — | 75.0 (19.4 to 99.4) | 60.0 (14.7 to 94.7) | — |
| Disease Subtype: MCL | — | 100.0 (2.5 to 100.0) | — | — | — | — | 0 (0 to 97.5) | — | — | — | 70.0 (34.8 to 93.3) | — | 100.0 (2.5 to 100.0) | — | — |
| Disease Subtype: MZL | — | — | 100.0 (2.5 to 100.0) | 33.3 (0.8 to 90.6) | — | 0 (0 to 97.5) | — | — | — | 0 (0 to 97.5) | 50.0 (6.8 to 93.2) | — | 100.0 (2.5 to 100.0) | 50.0 (1.3 to 98.7) | — |
| Disease Subtype: SLL | 50.0 (1.3 to 98.7) | — | — | — | — | — | 100.0 (15.8 to 100.0) | — | — | — | — | — | — | — | — |
| Disease Subtype: WM | — | — | — | 100.0 (39.8 to 100.0) | — | 0 (0 to 97.5) | — | — | — | 100.0 (2.5 to 100.0) | 85.7 (42.1 to 99.6) | — | — | — | — |
| Disease Subtype: DLBCL | — | — | 0 (0 to 97.5) | 14.3 (0.4 to 57.9) | 33.3 (7.5 to 70.1) | — | — | 0 (0 to 97.5) | 100.0 (15.8 to 100.0) | — | 25.0 (10.7 to 44.9) | 12.5 (0.3 to 52.7) | — | — | — |
PFS was defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression (PD) or death from any cause. PD: ≥ 25% increase in serum IgM level from lowest nadir (requires confirmation) and/or progression in clinical features attributable to the disease. Kaplan-Meier (KM) estimate were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; other NHL; DLBCL.
| months | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Subtype: CLL | NA (NA to NA) | NA (20.8 to NA) | 31.8 (NA to NA) | NA (8.3 to NA) | — | 39.6 (NA to NA) | — | NA (NA to NA) | — | — | NA (NA to NA) | — | — | — | NA (NA to NA) |
| Disease Subtype: DLBCL | — | — | 1.4 (NA to NA) | 1.5 (1.1 to 5.0) | 2.5 (1.2 to 11.0) | — | — | 1.2 (NA to NA) | NA (NA to NA) | — | 2.8 (1.5 to 5.3) | 2.3 (1.4 to 4.1) | — | — | — |
| Disease Subtype: FL | — | 8.2 (5.3 to 11.1) | 5.3 (NA to NA) | 5.6 (1.0 to NA) | — | 12.3 (5.4 to 19.3) | — | NA (NA to NA) | 19.4 (NA to NA) | 19.4 (NA to NA) | 11.0 (5.1 to 21.9) | — | — | — | — |
| Disease Subtype: MCL | — | 21.6 (NA to NA) | — | — | — | — | 5.4 (NA to NA) | — | — | — | 27.6 (16.8 to NA) | — | — | — | — |
| Disease Subtype: other NHL | 13.7 (5.5 to 21.9) | — | 6.0 (NA to NA) | NA (2.5 to NA) | — | 2.6 (1.2 to 4.0) | 56.9 (NA to NA) | — | — | NA (6.6 to NA) | NA (8.6 to NA) | — | NA (5.6 to NA) | NA (5.4 to NA) | — |
DOR was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of definite disease progression or death from any cause. CR and PR are defined in outcome measure# 2. PD is defined in outcome measure #6. KM estimates were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL
| months | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Subtype: CLL | NA (NA to NA) | NA (15.2 to NA) | 26.5 (NA to NA) | NA (NA to NA) | — | 34.1 (NA to NA) | — | NA (NA to NA) | — | — | NA (NA to NA) | — | — | — | NA (NA to NA) |
| Disease Subtype: FL | — | — | — | 3.0 (NA to NA) | — | 13.8 (NA to NA) | — | NA (NA to NA) | 16.6 (NA to NA) | 6.3 (NA to NA) | 17.3 (2.3 to NA) | — | NA (NA to NA) | NA (4.4 to NA) | — |
| Disease Subtype: MCL | — | 10.7 (NA to NA) | — | — | — | — | — | — | — | — | 24.9 (14.0 to NA) | — | 2.8 (NA to NA) | — | — |
| Disease Subtype: SLL | 19.3 (NA to NA) | — | — | — | — | — | 51.4 (NA to NA) | — | — | — | — | — | — | — | — |
| Disease Subtype: MZL | — | — | 3.3 (NA to NA) | 2.5 (NA to NA) | — | — | — | — | — | — | NA (NA to NA) | — | 8.2 (NA to NA) | NA (NA to NA) | — |
| Disease Subtype: WM | — | — | — | NA (20.1 to NA) | — | — | — | — | — | NA (NA to NA) | NA (13.9 to NA) | — | — | — | — |
| Disease Subtype: DLBCL | — | — | — | 3.9 (NA to NA) | NA (6.4 to NA) | — | — | — | NA (NA to NA) | — | 8.3 (1.4 to 23.5) | NA (NA to NA) | — | — | — |
TTR was defined as the interval from start of treatment to the first documentation of CR or PR. CR and PR are defined in outcome measure# 2. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL.
| months | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Subtype: CLL | 2.7 (2.7 to 2.7) | 5.6 (5.4 to 5.8) | 5.4 (5.4 to 5.4) | 5.6 (4.6 to 8.0) | — | 5.6 (5.6 to 5.6) | — | 5.4 (4.4 to 5.9) | — | — | 5.9 (5.4 to 6.8) | — | — | — | 5.5 (2.7 to 5.9) |
| Disease Subtype: FL | — | — | — | 2.6 (2.6 to 2.6) | — | 5.5 (5.5 to 5.5) | — | 2.8 (2.8 to 2.8) | 2.8 (2.8 to 2.8) | 13.0 (13.0 to 13.0) | 3.7 (2.8 to 11.0) | — | 3.9 (2.6 to 9.2) | 2.9 (2.6 to 4.6) | — |
| Disease Subtype: MCL | — | 10.8 (10.8 to 10.8) | — | — | — | — | — | — | — | — | 2.8 (2.8 to 8.4) | — | 2.8 (2.8 to 2.8) | — | — |
| Disease Subtype: SLL | 2.7 (2.7 to 2.7) | — | — | — | — | — | 5.5 (5.4 to 5.6) | — | — | — | — | — | — | — | — |
| Disease Subtype: MZL | — | — | 2.8 (2.8 to 2.8) | 2.9 (2.9 to 2.9) | — | — | — | — | — | — | 2.7 (2.7 to 2.8) | — | 2.7 (2.7 to 2.7) | 2.8 (2.8 to 2.8) | — |
| Disease Subtype: WM | — | — | — | 2.8 (2.6 to 3.0) | — | — | — | — | — | 17.5 (17.5 to 17.5) | 4.1 (2.8 to 9.1) | — | — | — | — |
| Disease Subtype: DLBCL | — | — | — | 1.6 (1.6 to 1.6) | 1.8 (1.4 to 4.6) | — | — | — | 1.9 (1.1 to 2.8) | — | 1.5 (1.3 to 13.0) | 1.6 (1.6 to 1.6) | — | — | — |
Achieving Minimal Residual Disease was defined as \< 1 leukemia cell/10,000 leukocytes (10-4) in participants who have also achieved a CR. CR is defined in outcome measure #2.
| percentage of participants | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Minimal Residual Negative Disease (< 1 Leukemia Cell/10,000 Leukocytes) During the Dose Escalation Phase and Dose Expansion Phase in Participants With CLL | 0 | 40 | 0 | 16.7 | — | 0 | — | 0 | — | — | 28.6 | — | — | — | 20.7 |
AUCtau was defined as concentration of drug over time. Area under the concentration verses time curve over the dosing interval (AUctau). The data for AUCtau is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.
| ng*h/mL | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Group V Single Agent Tirabrutinib |
|---|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter: AUCtau of Tirabrutinib 80 mg | 984.0 ± 342.18 | 1205.6 ± 245.89 | 1794.1 ± 181.15 | 1251.6 ± 387.46 | 1088.8 ± 545.52 |
Cmax was defined as the maximum observed concentration of drug. The data for Cmax is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.
| ng/mL | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Group V Single Agent Tirabrutinib |
|---|---|---|---|---|---|
| PK Parameter: Cmax of Tirabrutinib 80 mg | 192.3 ± 58.21 | 219.5 ± 12.02 | 304.7 ± 34.67 | 246.3 ± 11.37 | 215.2 ± 66.10 |
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) |
|---|---|---|---|---|---|---|
| PK Parameter: AUCtau of Idelalisib When Given in Combination With Tirabrutinib | 6620.6 ± 661.19 | 5433.2 ± 1287.95 | 6735.0 ± 1859.79 | 9488.0 ± 3263.44 | 19305.4 ± 5616.53 | 7093.0 ± 4025.04 |
Cmax was defined as the maximum observed concentration of drug.
| ng/mL | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) |
|---|---|---|---|---|---|---|
| PK Parameter: Cmax of Idelalisib When Given in Combination With Tirabrutinib | 1920.0 ± 252.39 | 1893.3 ± 750.82 | 1324.8 ± 389.65 | 1790.0 ± 268.70 | 3325.0 ± 481.28 | 1844.0 ± 518.58 |
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) |
|---|---|---|---|---|---|---|
| PK Parameter: AUCtau of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib | 19922.6 ± 9354.47 | 22519.6 ± 8233.77 | 41327.5 ± 20049.44 | 49192.7 ± 15719.52 | 36824.3 ± 9670.67 | 225371.5 ± 22931.89 |
Cmax was defined as the maximum observed concentration of drug.
| ng/mL | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) |
|---|---|---|---|---|---|---|
| PK Parameter: Cmax of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib | 2723.3 ± 1045.10 | 2760.0 ± 1105.31 | 2542.5 ± 1820.54 | 3415.0 ± 360.62 | 2592.5 ± 503.48 | 3682.0 ± 1950.35 |
AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) |
|---|---|---|---|---|---|---|
| PK Parameter: AUCtau of Entospletinib When Given in Combination With Tirabrutinib | 7738.7 ± 1793.68 | 4266.2 ± 1574.30 | 9968.3 ± 295.69 | 14027.8 ± 6979.18 | 12959.9 ± 2250.66 | 6196.8 ± 1018.98 |
Cmax was defined as the maximum observed concentration of drug.
| ng/mL | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) |
|---|---|---|---|---|---|---|
| PK Parameter: Cmax of Entospletinib When Given in Combination With Tirabrutinib | 876.0 ± 367.98 | 707.7 ± 397.04 | 697.0 ± 313.93 | 1498.7 ± 619.57 | 1330.7 ± 382.0 | 861.0 ± 276.17 |
Collected over Up to 441 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | 2/8 (25%) | 3/8 (37.5%) | 8/8 (100%) |
| Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | 6/25 (24%) | 13/25 (52%) | 24/25 (96%) |
| Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | 1/9 (11.1%) | 2/9 (22.2%) | 9/9 (100%) |
| Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | 2/5 (40%) | 4/5 (80%) | 5/5 (100%) |
| Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | 0/6 (0%) | 4/6 (66.7%) | 6/6 (100%) |
| Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | 8/78 (10.3%) | 36/78 (46.2%) | 73/78 (93.6%) |
| Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | 2/8 (25%) | 2/8 (25%) | 5/8 (62.5%) |
| Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | 1/6 (16.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | 1/7 (14.3%) | 7/7 (100%) | 7/7 (100%) |
| Group V Single Agent Tirabrutinib 80 mg | 3/29 (10.3%) | 10/29 (34.5%) | 29/29 (100%) |
| Group VI Single Agent Tirabrutinib: CLL | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Group VI Single Agent Tirabrutinib: NHL | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/3 | 0/8 | 0/4 | 1/25 | 0/9 | 0/5 | 0/3 | 0/6 | 0/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 1/3 | 0/3 |
| Atrial fibrillationCardiac disorders | 0/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 1/3 | 1/6 | 0/3 | 0/3 | 1/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 0/3 | 0/6 | 0/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| Clostridium difficile colitisInfections and infestations | 0/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 0/3 | 0/6 | 1/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| DiverticulitisInfections and infestations | 1/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 0/3 | 0/6 | 0/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| PneumoniaInfections and infestations | 0/3 | 0/8 | 1/4 | 3/25 | 0/9 | 1/5 | 1/3 | 0/6 | 0/3 | 0/3 | 2/78 | 0/8 | 1/6 | 1/7 | 2/29 | 0/3 | 0/3 |
| Streptococcal infectionInfections and infestations | 0/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 0/3 | 0/6 | 1/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 0/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 0/3 | 1/6 | 0/3 | 0/3 | 2/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 1/3 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 1/3 | 0/6 | 0/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/3 | 0/8 | 0/4 | 0/25 | 0/9 | 0/5 | 0/3 | 0/6 | 1/3 | 0/3 | 0/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| Event | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib 80 mg | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 3/3 | 2/8 | 1/4 | 3/25 | 1/9 | 1/5 | 0/3 | 2/6 | 0/3 | 1/3 | 14/78 | 0/8 | 1/6 | 1/7 | 3/29 | 0/3 | 0/3 |
| ContusionInjury, poisoning and procedural complications | 3/3 | 2/8 | 0/4 | 4/25 | 0/9 | 1/5 | 0/3 | 2/6 | 0/3 | 1/3 | 15/78 | 0/8 | 0/6 | 0/7 | 6/29 | 0/3 | 0/3 |
| ConstipationGastrointestinal disorders | 0/3 | 2/8 | 1/4 | 3/25 | 1/9 | 4/5 | 0/3 | 2/6 | 0/3 | 1/3 | 11/78 | 0/8 | 2/6 | 3/7 | 8/29 | 0/3 | 0/3 |
| NauseaGastrointestinal disorders | 2/3 | 2/8 | 1/4 | 3/25 | 1/9 | 2/5 | 0/3 | 1/6 | 0/3 | 0/3 | 18/78 | 1/8 | 2/6 | 1/7 | 10/29 | 0/3 | 0/3 |
| StomatitisGastrointestinal disorders | 2/3 | 1/8 | 0/4 | 3/25 | 0/9 | 0/5 | 1/3 | 0/6 | 0/3 | 0/3 | 0/78 | 0/8 | 2/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| FatigueGeneral disorders | 0/3 | 1/8 | 1/4 | 3/25 | 1/9 | 2/5 | 1/3 | 4/6 | 2/3 | 0/3 | 21/78 | 0/8 | 1/6 | 1/7 | 8/29 | 1/3 | 0/3 |
| Oedema peripheralGeneral disorders | 2/3 | 0/8 | 1/4 | 3/25 | 1/9 | 1/5 | 1/3 | 0/6 | 0/3 | 1/3 | 2/78 | 0/8 | 0/6 | 1/7 | 6/29 | 0/3 | 0/3 |
| ConjunctivitisInfections and infestations | 2/3 | 0/8 | 0/4 | 1/25 | 1/9 | 1/5 | 0/3 | 0/6 | 0/3 | 0/3 | 2/78 | 0/8 | 0/6 | 0/7 | 0/29 | 0/3 | 0/3 |
| Herpes zosterInfections and infestations | 1/3 | 1/8 | 0/4 | 0/25 | 0/9 | 0/5 | 2/3 | 1/6 | 0/3 | 0/3 | 0/78 | 0/8 | 1/6 | 1/7 | 1/29 | 0/3 | 0/3 |
| Lower respiratory tract infectionInfections and infestations | 1/3 | 1/8 | 1/4 | 1/25 | 0/9 | 0/5 | 0/3 | 1/6 | 1/3 | 0/3 | 6/78 | 0/8 | 0/6 | 0/7 | 5/29 | 2/3 | 0/3 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 2 | 12 | 2 | 4 | 0 | 1 | 1 | 0 | 26 | 4 | 3 | 3 | 8 | 1 | 0 | 72 |
| >=65 years | 1 | 5 | 2 | 13 | 7 | 1 | 3 | 5 | 2 | 3 | 52 | 4 | 3 | 4 | 21 | 2 | 3 | 131 |
| Age, Continuous(years) | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66 ± 4.4 | 65 ± 9.7 | 62 ± 12.0 | 64 ± 13.2 | 73 ± 8.9 | 55 ± 12.8 | 70 ± 7.0 | 66 ± 11.1 | 67 ± 5.1 | 67 ± 1.2 | 68 ± 11.7 | 63 ± 11.9 | 59 ± 11.8 | 64 ± 14.4 | 70 ± 9.4 | 66 ± 4.0 | 74 ± 4.4 | 67 ± 11.3 |
| Sex: Female, Male(Participants) | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 0 | 10 | 4 | 2 | 0 | 3 | 0 | 2 | 25 | 3 | 3 | 3 | 12 | 1 | 2 | 75 |
| Male | 0 | 6 | 4 | 15 | 5 | 3 | 3 | 3 | 3 | 1 | 53 | 5 | 3 | 4 | 17 | 2 | 1 | 128 |
| Ethnicity (NIH/OMB)(Participants) | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 8 | 4 | 23 | 7 | 4 | 3 | 6 | 2 | 3 | 51 | 7 | 4 | 1 | 23 | 2 | 3 | 154 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 0 | 27 | 1 | 2 | 6 | 6 | 1 | 0 | 48 |
| Race (NIH/OMB)(Participants) | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 3 | 7 | 3 | 17 | 3 | 3 | 3 | 6 | 3 | 3 | 46 | 5 | 4 | 1 | 21 | 3 | 3 | 134 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 6 | 6 | 1 | 0 | 0 | 0 | 0 | 30 | 3 | 2 | 6 | 8 | 0 | 0 | 62 |
| Region of Enrollment(Participants) | Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID) | Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD) | Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD) | Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD) | Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD) | Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg) | Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg) | Group V Single Agent Tirabrutinib | Group VI Single Agent Tirabrutinib: CLL | Group VI Single Agent Tirabrutinib: NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 0 | 2 | 2 | 8 | 6 | 1 | 1 | 0 | 1 | 2 | 35 | 7 | 4 | 7 | 7 | 0 | 0 | 83 |
| United Kingdom | 0 | 4 | 2 | 13 | 2 | 2 | 0 | 4 | 2 | 1 | 35 | 1 | 0 | 0 | 12 | 2 | 3 | 83 |
| United States | 3 | 2 | 0 | 4 | 1 | 2 | 2 | 2 | 0 | 0 | 8 | 0 | 2 | 0 | 10 | 1 | 0 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Sep 2024, 111 months.
Results were first posted in Jun 2025, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirabrutinib